Skip to Main Content
Table 2.

Response in evaluable patients based on RECIST v1.1 assessed by investigator reviewa

N = 2595% CI
Overall response rate, n (%) 3 (12) 2.5–31.2 
Clinical benefit rateb, n (%) 5 (20) 6.8–40.7 
Best overall responsec, n (%) 
 CR 0 (0) 0.0–13.7 
 PR 3 (12) 2.5–31.2 
 SD 4 (16) 4.5–36.1 
 Progressive disease 15 (60) 38.7–78.9 
 No assessmentd 3 (12) 2.5–31.2 
N = 2595% CI
Overall response rate, n (%) 3 (12) 2.5–31.2 
Clinical benefit rateb, n (%) 5 (20) 6.8–40.7 
Best overall responsec, n (%) 
 CR 0 (0) 0.0–13.7 
 PR 3 (12) 2.5–31.2 
 SD 4 (16) 4.5–36.1 
 Progressive disease 15 (60) 38.7–78.9 
 No assessmentd 3 (12) 2.5–31.2 

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; RECIST, Response Evaluation Criteria in Solid Tumors.

aIncludes patients with measurable disease at baseline based on RECIST v1.1 as assessed by investigator review who received ≥1 pembrolizumab dose.

bCR + PR + (SD for ≥24 weeks).

cAll responses were confirmed.

dSignifies patients who did not have any postbaseline imaging studies.

Close Modal

or Create an Account

Close Modal
Close Modal